Skip to search formSkip to main contentSkip to account menu

BNP 1350

Known as: BNP-1350, BNP1350, DB 172 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
The prognosis for patients with high-grade glioma remains dismal illustrating the need for the development of chemotherapeutic… 
2016
2016
The poor prognosis of malignant glioma patients highlights the need to develop low toxicity, tumor specific agents with the… 
Highly Cited
2005
Highly Cited
2005
Purpose: A phase II trial of the novel camptothecin karenitecin (BNP1350) was conducted to determine its efficacy and… 
Review
2005
Review
2005
Purpose: A phase II trial of the novel camptothecin karenitecin (BNP1350) was conducted to determine its efficacyand tolerability… 
2004
2004
PurposeBNP1350 (7-[(2-trimethylsilyl)ethyl]-20(S)-camptothecin, karenitecin), a highly lipophilic camptothecin, a high percentage… 
2004
2004
7554 Background: To determine the efficacy and safety of the novel camptothecin, karenitecin (BNP1350), in patients with… 
2002
2002
The novel camptothecin derivative BNP1350 (7‐[2‐trimethylsilyl)ethyl]‐20(S)‐camptothecin), also known as Karenitecin, has been… 
Highly Cited
2000
Highly Cited
2000
BNP1350, 7‐[(2‐trimethylsilyl)ethyl]‐20(S)‐camptothecin, is a novel semi‐synthetic, highly lipophilic, silicon‐containing… 
2000
2000
Cellular topoisomerase I is an important target in cancer chemotherapy. A novel karenitecin, BNP1350, is a topoisomerase I…